Cooley: Landos Biopharma to Be Acquired by AbbVie
March 27, 2024
March 27, 2024
NEW YORK, March 27 -- Cooley, a law firm, issued the following news release:
Cooley advised Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases, on its definitive agreement under which it will be acquired by AbbVie.
Partners Eric Blanchard and Kevin Cooper led the Cooley team advising Landos.
Under the terms of the agreement, AbbVie . . .
Cooley advised Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases, on its definitive agreement under which it will be acquired by AbbVie.
Partners Eric Blanchard and Kevin Cooper led the Cooley team advising Landos.
Under the terms of the agreement, AbbVie . . .